Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.20.2
Intangible Assets (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Mar. 19, 2018
Amortization expense $ 397,664 $ 397,664  
Future amortization expense, year one 795,000    
Future amortization expense, year two $ 788,000    
CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member]      
Purchase price     $ 8,000,000
Transaction cost     1,782
Recognition of deferred tax liability     3,037,147
Intangible asset, tax basis     $ 1,782